Relay 10-Q: $848.6M Cash Into 2029, Q3 Loss $81.7M, ATM Upsized to $463M
RLAY has more than doubled off its 52-week low of $5.95.
Summary
Relay's Q3 10-Q confirms $848.6M in cash with runway into 2029 against an $81.7M quarterly loss, and details $456.0M raised this year through a May follow-on and ATM sales, with the ATM shelf now upsized to $463.0M.
Key Events · Earnings and Guidance · RLAY
-
Q3 Loss Widens on Higher R&D
Net loss was $81.7 million, or $0.37 per share, versus $74.1 million ($0.43) a year earlier. R&D rose to $77.1 million from $68.3 million on clinical trial costs plus non-recurring lease termination charges.
-
Cash of $848.6M, Runway Into 2029
Cash, equivalents and investments totaled $848.6 million at September 30, down from $910.9 million at June 30. Management projects funding into 2029.
-
$456M Raised Via Follow-On and ATM
Nine-month financing brought in $466.9 million, including $296.8 million net from the May 2026 follow-on of 26,354,167 shares at $12.00 and $159.2 million net from 16,006,569 ATM shares.
-
ATM Shelf Upsized to $463M
In August 2026 the sales agreement with TD Securities was amended to raise the at-the-market program from $250.0 million to $463.0 million; no shares were sold under it in Q3.
Analysis · RLAY · Life Sciences
The headline numbers were already out via this morning's press release, so the market has seen the $848.6M cash pile and the $81.7M quarterly loss. What the 10-Q adds is the plumbing behind them: $456.0M of equity raised in nine months (a $296.8M May follow-on at $12.00 plus $159.2M of ATM sales), an ATM shelf enlarged to $463.0M in August, and authorized shares lifted to 450 million in June — a company that has been steadily issuing stock to fund a pipeline whose Phase 3 ReDiscover-2 readout is still years out. Cash fell $62.3M in the quarter while R&D rose to $77.1M from $68.3M, so the burn is accelerating even with the runway intact. Also newly detailed: a $1.5M lease termination at One Kendall Square and an October 6 settlement stipulation in the derivative suit over director pay, still awaiting court approval.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $18.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $5.95 to $21.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.